PREVENT Cancer Preclinical Drug Development Program (PREVENT) 2024

IDIQ

Description

Provide the production of vaccines and biologicals for cancer prevention. The PREVENT program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. Research priority areas include immunoprevention, chemoprevention, and clinically translatable biomarkers.

Overview

Ceiling

$149,995,000

Primary Sponsoring Agency

National Cancer Institute (NCI) [HHS - NIH]

Who Can Use

One Agency

Primary NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Primary PSC

AN12 - Health R&D Services; Health Care Services; Applied Research

Primary Set Aside

None

Extent Competed

Full And Open Competition

Related Opportunity

PREVENT IDIQ MATO RFP (75N91023R00024)

Predecessor

PREVENT Cancer Preclinical Drug Development Program (cGMP)

PREVENT Cancer Preclinical Drug Development Program (PREVENT) 2024 awarded by National Cancer Institute (NCI) in January 2024 accepts orders through January 2029. The IDIQ has a reported ceiling of $149,995,000, and as of today, $2,690,637 has been obligated through the vehicle with a total reported backlog of $1,758,807. The IDIQ was awarded full & open and has a primary NAICS code of 541714.

Award Hierarchy

Vehicle

PREVENT Cancer Preclinical Drug Development Program (PREVENT) 2024

Indefinite Delivery Vehicles

Prime Contracts

Subcontracts

Status

Period of Performance

1/25/24

Start Date

1/24/29

Ordering Period End Date

34.0% Complete

Task Order Obligations and Backlog

$2.7M

Total Obligated

$2.7M

Current Award

$4.4M

Potential Award

60% Funded

$0.0

Funded Backlog

$1.8M

Total Backlog

Vehicle Award Share

Contractors with greatest percentage of obligations for PREVENT Cancer Preclinical Drug Development Program (PREVENT) 2024

Vehicle Award Share

Federal Award Analysis